{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "foscarnet" in Standardized Name (exact match)
Showing 1 - 1 of 1 results
Status:
US Approved Rx
(2021)
Source:
ANDA212483
(2021)
Source URL:
First approved in 1991
Source:
NDA020068
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic
pyrophosphate that inhibits replication of herpesviruses in
vitro including cytomegalovirus (CMV) and herpes simplex
virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective
inhibition at the pyrophosphate binding site on virusspecific
DNA polymerases at concentrations that do not
affect cellular DNA polymerases. FOSCAVIR does not
require activation (phosphorylation) by thymidine kinase or
other kinases and therefore is active in vitro against HSV
TK deficient mutants and CMV UL97 mutants. Thus, HSV
strains resistant to acyclovir or CMV strains resistant to
ganciclovir may be sensitive to FOSCAVIR.